- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01232829
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the 6-month survival of patients with previously treated metastatic pancreas cancer treated with gamma secretase RO4929097.
II. To determine the adverse events of RO4929097 in this patient population. III. To correlate changes in tumor markers with RO4929097 exposure.
SECONDARY OBJECTIVES:
I. To evaluate the response rate and overall survival of this population treated with RO4929097.
II. To correlate clinical outcome with tumor markers (including stem cell markers) obtained from pre- and post- treatment biopsies. (exploratory) III. To assess variants in genes involved in RO4929097 disposition and their relation to RO4929097 exposure.
OUTLINE: This is a multicenter study.
Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 orally (PO) once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies.
After completion of study therapy, patients are followed up periodically for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Cancer Center - Anschutz Cancer Pavilion
-
Denver, Colorado, United States, 80217-3364
- University of Colorado
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma
- Not amenable to potentially curative surgical resection
At least 1 prior regimen of chemotherapy, preferably gemcitabine-based, for metastatic disease
- Evidence of disease progression
- Measurable disease defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan
Available archived tumor tissue (baseline core biopsies or surgical tumor blocks)
- No diagnosis by fine-needle aspiration only
- No known brain metastases
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (Karnofsky 70-100%)
- White blood cell count (WBC) ≥ 3,000/mm³
- Absolute neutrophil count (ANC) ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9 g/dL
- Total bilirubin normal
- Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- Willingness to undergo 2 tumor biopsies, if required
- Fertile patients must use 2 forms of contraception (i.e., barrier contraception and one other method of contraception) ≥ 4 weeks prior to, during, and for ≥ 12 months after completion of therapy
- Negative pregnancy test
- Not pregnant or nursing
- Able to swallow pills
- No patients with malabsorption syndrome or other condition that would interfere with intestinal absorption
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma secretase inhibitor RO4929097
- Not serologically positive for hepatitis A, B, or C
- No history of liver disease, other forms of hepatitis, or cirrhosis
- No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia despite adequate electrolyte supplementation
No uncontrolled intercurrent illness including, but not limited to, any of the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia other than chronic, stable atrial fibrillation
- Psychiatric illness/social situations that would limit compliance with study requirements
- No baseline QTcF > 450 msec (male) or QTcF > 470 msec (female)
- No other malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin or carcinoma in-situ of the uterine cervix
- No combination antiretroviral therapy for HIV-positive patients
- Recovered to < Common Toxicity Criteria for Adverse Effects (NCI CTCAE) grade 2 toxicities from prior therapy
- More than 3 weeks since prior chemotherapy for metastatic disease (6 weeks for carmustine or mitomycin C)
- At least 4 weeks since prior radiotherapy
Concurrent low-molecular weight heparin (LMWH) or full-dose coumadin allowed
- International normalized ratio (INR) must be monitored as clinically indicated
- No other concurrent investigational agents
No concurrent strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers, including the following:
Strong inhibitors: Amiodarone, erythromycin, clarithromycin, grapefruit juice, isoniazid, ketoconazole, itraconazole, or nefazodone
- Patients taken off strong inhibitors allowed provided they have ≥ 1-week washout period
Strong inducers: Carbamazepine, pentobarbital, phenobarbital, phenytoin, Rifabutin, Rifampin, or St. John wort
- Patients taken off strong inducers allowed provided they have ≥ 2-week washout period
- No concurrent antiarrhythmics or other medications known to prolong QTc
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (RO4929097)
Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies. |
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival Rate
Time Frame: 6 months
|
The primary endpoint of the study was 6-month survival.
The proportion of successes was estimated by the number of successes divided by the total number of evaluable patients.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: From registration to death due to any cause, assessed up to 2 years
|
Survival was estimated using the Kaplan-Meier (1958) method.
|
From registration to death due to any cause, assessed up to 2 years
|
Time to Disease Progression
Time Frame: From registration to documentation of disease progression, assessed up to 2 years
|
Eighteen patients were evaluable for the time to disease progression endpoint.
|
From registration to documentation of disease progression, assessed up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wells Messersmith, University of Colorado Cancer Center - Anschutz Cancer Pavilion
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2011-02537 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U01CA070095 (U.S. NIH Grant/Contract)
- P30CA046934 (U.S. NIH Grant/Contract)
- CDR0000687335
- 10-0273 (Other Identifier: Colorado Multiple Institutional Review Board)
- 8490 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma of the Pancreas
-
Centre Leon BerardMerck Sharp & Dohme LLC; Debiopharm International SACompletedAdenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonFrance
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
Kyowa Hakko Kirin Pharma, Inc.Teva PharmaCompletedAdenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
-
University of Michigan Rogel Cancer CenterCompletedAdenocarcinoma of the PancreasUnited States
-
National Cancer Institute, NaplesRecruitingAdenocarcinoma of the PancreasItaly, Spain
-
West Virginia UniversityRecruitingAdenocarcinoma of the PancreasUnited States
-
Baptist Health South FloridaAstraZenecaTerminatedAdenocarcinoma of the PancreasUnited States
-
Institut de Recherches Internationales ServierNot yet recruitingMetastatic Adenocarcinoma of the PancreasJapan
-
National Taiwan University HospitalRecruitingDuctal Adenocarcinoma of the PancreasTaiwan
-
Eastern Regional Medical CenterTerminatedMetastatic Adenocarcinoma of the PancreasUnited States
Clinical Trials on gamma-secretase/Notch signalling pathway inhibitor RO4929097
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
National Cancer Institute (NCI)M.D. Anderson Cancer CenterTerminatedStage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)TerminatedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
National Cancer Institute (NCI)WithdrawnStage IV Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedAdult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor | Adult Brain Stem GliomaCanada
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificCanada
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedAdenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States